University of Oxford
VC Fund
Oxford, United Kingdom
University of Oxford is a VC fund in Oxford focused on Health Care and Biotechnology. Oxford is a collegiate university, consisting of the central University and colleges. The central University is composed of academic departments and research centres, administrative departments, libraries and museums. The 38 colleges are self-governing and financially independent institutions, which are related to the central University in afederal system. There are also six permanent private halls, which were founded by different Christian denominations and which still retain their Christian character.The collegiate system is at the heart of the University’s success, giving students and academics the benefits of belonging both to a large, internationally renowned institution and to a small, interdisciplinary academic community. It brings together leading academics and students across subjects and year groups and from different cultures and countries, helping to foster the intense interdisciplinary approach that inspires much of the outstanding research, <a href="https://www.dissertationcorp.co.uk/">dissertation help</a> achievement of the University and makes Oxford a leader in so many fields.
- Total investments:
- 36
- Last investment:
- Lead investor:
- 6%
Last updated:
For AI agents: llms.txt
Industries University of Oxford invests in
Stages University of Oxford invests in
Countries University of Oxford invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Cameron Hepburn
|
|||
Crispin Davis
|
|||
Marilyn Thomas
|
|||
Max Little
|
|||
Paul Timmers
|
Investment Focus
Industry
- Health Care 13 (36%)
- Biotechnology 12 (33%)
- Medical 10 (28%)
- Artificial Intelligence 5 (14%)
- Software 4 (11%)
Stage
- Series A 13 (36%)
- Series B 6 (17%)
- Seed 4 (11%)
- Funding Round 4 (11%)
- Venture - Series Unknown 4 (11%)
Country
- United Kingdom 29 (81%)
- United States 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Cameron Hepburn
Professor of Environmental Economics
|
Professor of Environmental Economics | Total investments: 2 | Find email | |
|
Crispin Davis
Trustee and Member of the University Board
|
Trustee and Member of the University Board | Total investments: 0 | Find email | |
|
Marilyn Thomas
Honorary Member
|
Honorary Member | Total investments: 0 | Find email | |
|
Max Little
Honorary Associate Professor
|
Honorary Associate Professor | Total investments: 0 | Find email | |
|
Paul Timmers
Research Associate University of Oxford
|
Research Associate University of Oxford | Total investments: 0 | Find email | |
| See all 23 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
RQ Bio
|
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza with the goal of providing immediate, powerful, and long-lasting protection against severe viral disease in immunocompromised and high-risk subjects. The company's mission is to deliver "instant immunity" through passiveimmunization, helping protect vulnerable populations such as the elderly, newborns, and immunocompromised patients from severe infectious diseases. The company specializes in the discovery and development of broad-spectrum antiviral antibodies that are engineered to remain effective even as viruses evolve. Its scientific approach combines virology, antibody engineering, computational biology, and immune-directed discovery techniques to identify potent antibodies that target conserved regions of viral proteins, reducing the risk of resistance caused by viral mutations.RQ Bio's lead programs focus on infectious diseases such as influenza, COVID-19, respiratory syncytial virus (RSV), and cytomegalovirus (CMV). The company is currently developing long-acting monoclonal antibodies designed to provide once-yearly protection against seasonal influenza, particularly for individuals at high risk of severe disease. | $112.5M / Series A / Jun 24, 2026 | |
Bizumi
|
Bizumi specialises in personalised, sustainable business travel, delivered by its end-to-end travel management platform. Our vision is to be the world’s leading personalised business travel management company prioritising and satisfying the needs of the traveller, and empowering organisations to achieve sustainability goals through intelligent,informed decision making. | $53.2K / Convertible Note / Dec 09, 2025 | |
Wild Bioscience
|
Wild Bioscience is a crop improvement company that provides carbon mitigation, yield enhancement, and farm productivity solutions. | $60.5M / Series A / Oct 16, 2025 | |
OXCCU
|
OXCCU develops renewable energy technology with the goal of achieving a circular economy for fuels, chemicals, and plastics. The technology offered by the company combines carbon dioxide from the atmosphere with hydrogen from water and renewable electricity to produce fuels, chemicals, and biodegradable plastics. | $27.9M / Series B / Sep 29, 2025 | |
Ultromics
|
Ultromics develops AI-powered software solutions to assist in cardiovascular disease diagnosis through echocardiography. The company provides platforms that support clinicians in interpreting echocardiogram data by applying machine learning to detect patterns and abnormalities that may indicate heart conditions. Ultromics offers its flagshipproduct, EchoGo, which automates the analysis of echocardiograms and delivers quantitative reports on cardiac function and structure. The software integrates with existing clinical workflows and is designed to enhance decision-making consistency while reducing variability in scan interpretation. Ultromics focuses on leveraging data-driven approaches to support early detection of conditions such as heart failure and coronary artery disease. Its technology is built on research collaborations and large-scale clinical datasets, aiming to improve diagnostic outcomes and support clinical efficiency. | $55M / Series C / Jul 31, 2025 | |
Seloxium
|
Seloxium helps mining, refining, and industrial companies meet their ESG goals by turning wastewater into a highly profitable and sustainable resource. The foundation of Seloxium is cutting-edge research that allows for the environmentally friendly extraction of essential metals at a fraction of the typical carbon footprint while simultaneouslykeeping harmful metals out of the environment. | $6M / Seed / Mar 20, 2025 | |
OrganOx
|
OrganOx Limited was founded in 2008 to exploit normothermic preservation technology invented by Prof Peter Friend and colleagues and further developed by Prof Constantin Coussios at the University of Oxford. | $160M / Venture - Series Unknown / Feb 24, 2025 | |
Diffblue
|
Diffblue is changing the way software is developed using Artificial Intelligence (AI).Diffblue Cover, the company’s first product, automatically generates tests for Java code to enable development teams to deliver higher quality software, faster. Diffblue’s technology is developed by its team of leading experts in AI, software verification andsynthesis, and customers include Goldman Sachs and Amazon Web Services.Diffblue is backed by Oxford University, Oxford Sciences Innovation and Goldman Sachs and is headquartered in Oxford, UK. | $6.3M / Oct 30, 2024 | |
|
Diffblue
|
Diffblue is changing the way software is developed using Artificial Intelligence (AI).Diffblue Cover, the company’s first product, automatically generates tests for Java code to enable development teams to deliver higher quality software, faster. Diffblue’s technology is developed by its team of leading experts in AI, software verification andsynthesis, and customers include Goldman Sachs and Amazon Web Services.Diffblue is backed by Oxford University, Oxford Sciences Innovation and Goldman Sachs and is headquartered in Oxford, UK. | $6.3M / Series A / Oct 30, 2024 | |
FluoRok
|
FluoRok is revolutionizing the way fluorochemicals are produced globally. | $10.3M / Seed / Sep 23, 2024 | |
| See all 36 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does University of Oxford invest in?
University of Oxford invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 36 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact University of Oxford?
Public channels for University of Oxford include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at University of Oxford?
The team at University of Oxford includes Cameron Hepburn (Professor of Environmental Economics), Crispin Davis (Trustee and Member of the University Board) and Marilyn Thomas (Honorary Member), among 23 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
